Home Companies Catalysts Deep Dives
Lynparza olaparib APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaOncology
Launch2014-12-19
US LOE2027-09-08
Peak Sales Est$4500M
Formulations[{"id":"lynparza-oral","doses":"100mg, 150mg tablets","route":"Oral","setting":"PATIENT_SELF","frequ
Companies
AZN (ORIGINATOR)50%
MRK (CO_DEVELOPER)50%
Mechanism: PARP inhibitor
Expert: Poly(ADP-ribose) polymerase inhibitor that exploits synthetic lethality in homologous recombination-deficient tumors, particularly those with BRCA1/2 mutations.
Everyday: Blocks a protein that helps repair damaged DNA in cancer cells, causing cells with BRCA mutations to die.
Targets: ["PARP"]
Revenue History
PeriodRevenue ($M)
2023$2,789M
2024$2,612M
Q1 2025$620M
Q2 2025$610M
Programs (4)
IndicationStageKey StudyRegional Status
OC (BRCAm)APPROVEDSOLO-1[{"stage":"APPROVED","region":"US","approval_date":"2018-12-19"},{"stage":"APPRO
Pancreatic (gBRCAm)APPROVEDPOLO[{"stage":"APPROVED","region":"US","approval_date":"2019-12-27"},{"stage":"APPRO
mCRPC (HRRm)APPROVEDPROpel[{"stage":"APPROVED","region":"US","approval_date":"2020-05-19"},{"stage":"APPRO
BC (gBRCAm)APPROVEDOlympiA[{"stage":"APPROVED","region":"US","approval_date":"2022-03-11"},{"stage":"APPRO
Notes
PARP inhibitor. Merck partnership.
Data from Supabase · Updated 2026-03-24